¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"basic trauma life support"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • life table
    »ý¸íÇ¥
  • life insurance medicine
    »ý¸íº¸ÇèÀÇÇÐ
  • life insurance method
    »ý¸íº¸Çè¹ý
  • physical half life
    ¹°¸®Àû¹Ý°¨±â
  • shelf life
    ÀúÀå±â°£, º¸°ü±â°£
  • mean life span
    Æò±Õ¼ö¸í
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • birth trauma
    ºÐ¸¸¿Ü»ó, ¼Õ»ó.
  • blunt trauma
    µÐ»ó(µÐ»ó), µÐ±â¿Ü»ó(µÐ±â ¿Ü»ó).
  • head injury =h. trauma
    µÎºÎ¿Ü»ó(µÎºÎ¿Ü »ó), µÎºÎ¼Õ»ó(µÎºÎ¼Õ»ó).
  • head trauma
    µÎºÎ¿Ü»ó(ÔéÝ»èâß¿)
  • head trauma =h. injury
    µÎºÎ¿Ü»ó(µÎºÎ¿Ü»ó).
  • head trauma =h. injury
    µÎºÎ¿Ü»ó(ÔéÝ»èâß¿).
  • maxillofacial trauma
    ¾Ç¾È¸é ¿Ü»ó
  • mechanical trauma
    ±â°èÀû ¿Ü»ó(¡­¿Ü»ó).
  • membrane, trauma of tympanic
    °í¸·¿Ü»ó
  • nasal trauma
    ºñ¿Ü»ó
  • neck trauma
    °æºÎ¿Ü»ó
  • noise trauma
    ¼ÒÀ½<À½Çâ>(¼º) ¿Ü»ó(ËÛËô<ËôÌ´>ËÛËíË×).
  • noise trauma
    ¼ÒÀ½ [À½Çâ] (¼º) ¿Ü»ó
  • occlusal trauma
    ±³ÇÕ¼º ¿Ü»ó(Îáùêàõèâß¿).
  • penoscrotal trauma
    À½°æÀ½³¶¿Ü»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ACLS advanced cardiac life support; Assessment of Children's Language Comprehension
ELS Eaton-Lambert syndrome; electron loss spectroscopy; extended least square; extracorporeal life suppo...
ELSO Extracorporeal Life Support Organization
ELSS emergency life support system
ILSS integrated life support system; intraluminal somatostatin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
FAST Focused Abdominal Sonography for Trauma
HT Head trauma
MTOS Major Trauma Outcome Study
N.P.T.R. National Pediatric Trauma Registry
P.T.S. Pediatric Trauma Score
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • life cycle
    »ýȰȯ, »ýȰ ÁÖ±â
    »ý¹°ÀÇ »ýȰ»ç¿¡ ÀÖ¾î ÀÏ·ÃÀÇ Çö»ó.
  • life expectancy
    ¼ö¸í
    ¾î¶² ¿¬·É ¶Ç´Â ¿¬·ÉÃþÀÇ »ç¶÷ÀÌ ´õ »ì ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ´Â ¿¬¼ö·Î¼­ Åë°èÀûÀÎ Æò±Õ¿¡ ±âÃÊÇÑ °Í.
  • life habit
    »ýȰ ½À¼º, »ýȰ ½À°ü
    °°Àº »óȲ¿¡¼­ ¹Ýº¹µÈ ÇൿÀÇ ¾ÈÁ¤È­, ÀÚµ¿È­µÈ ¼öÇà. Á¼Àº Àǹ̷δ ¹Ýº¹¿¡ ÀÇÇÑ ±ÙÀ° ¿îµ¿À̳ª °Ç ¿îµ¿ÀÌ Á¤ÇüÈ­µÇ´Â °ÍÀ» ¸»ÇÏÁö¸¸, ÁÖ±âÀûÀ¸·Î ¹Ýº¹ÇÏ´Â ½Ä»ç³ª ¼ö¸é ½À°ü, dz¼Ó, ¹®È­ µî ³ÐÀº °ü½À¿¡ ´ëÇØ¼­µµ ½À°üÀ̶ó°í ÇÑ´Ù. ½À°üÀ̶õ Á¤ÇüÀûÀ̸ç ÀÚµ¿ÀûÀ¸·Î ¹ß»ýÇÏ´Â ¹ÝÀÀÀ̶ó´Â Á¡¿¡¼­ ÀÚÀ¯·ÎÀÌ º¯È­ÇÏ´Â ÀǵµÀû ¹ÝÀÀ°ú ±¸º°µÈ´Ù. ¶ÇÇÑ ½À°üÀº ½ÀµæµÈ °á°ú¶ó´Â Á¡¿¡¼­ ¼±ÃµÀû ¹ÝÀÀ°ú ±¸º°µÈ´Ù. ¼ú, ´ã¹è ¶Ç´Â ƯÁ¤ ¾à¹°ÀÇ »ó¿ëÀ̳ª, ¿­´ë, ÇÑ´ë¿¡¼­ÀÇ Àå±â »ýȰ, ¿ìÁÖºñÇà¿¡¼­ÀÇ ±â¾ÐÀ̳ª ¹«Áß·Â »óÅ¿¡ ´ëÇÑ ÀûÀÀ µî Ư¼öÇÑ ¿ÜÀûÀÎ »óȲ¿¡ ´ëÇÑ ¹ÝÀÀÀÇ Á¤ÇüÈ­´Â¡®¼øÈ­¡¯¶ó°í ÇÏ¿© ½À°ü°ú ±¸º°ÇÏ¿©¾ß ÇÑ´Ù.
  • life insurance
    »ý¸í º¸Çè
    »ç¶÷ÀÇ »ç¸Á ¶Ç´Â »ýÁ¸À» º¸Çè»ç°í·Î ÇÏ´Â ÀÏüÀÇ º¸Çè. Àκ¸ÇèÀÇ ´ëÇ¥ÀûÀÎ °ÍÀÌ´Ù. º¸ÇèÀÚ°¡ º¸Çè°è¾àÀÚ ¶Ç´Â Á¦3ÀÚÀÇ »ý»ç¿¡ °üÇÏ¿© ÀÏÁ¤ÇÑ ±Ý¾×
  • life insurance medicine
    »ý¸í º¸Çè ÀÇÇÐ
  • life phase
    »ýȰ»ó
  • life span
    ¼ö¸í
    °³Ã¼ÀÇ »ýÁ¸ ±â°£.
  • mean life expectancy
    Æò±Õ ¿©¸í
  • quality of life
    »îÀÇ Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
myelin basic proteins A group of 7 proteins produced from a single gene by alternate splicing found in central and peripheral nervous system myelin. The major basic protein (mbp) has long been of interest because it is the antigen, that, when injected into an animal, elicits a cellular immune response that produces the CNS autoimmune disease called experimental allergic encephalomyelitis (encephalomyelitis, allergic). In the peripheral nervous system, myelin basic protein 18.5 kD is often referred to as the p1 protein.
(12 Dec 1998)
haematoxylin-malachite green-basic fuchsin stain <technique> A stain for epoxy resin-extracted sections; semi-thick sections have their plastic dissolved out and the residual tissue is stained sequentially with the various dyes; nuclei and astrocytes are purplish-pink and myelin, lipid droplets, nucleoli, and oligodendrocytes are bright blue-green.
(05 Mar 2000)
fibroblast growth factor, basic A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro.
(12 Dec 1998)
artificial life Artificial life (AL, alife) is a scientific discipline in whichresearchers study life by creating computer programs that recreatebiological systems from scratch.
(09 Oct 1997)
biological half-life <biochemistry, biology> This is the time required for one-half of the total amount of a particular substance in a biological system to be consumed or broken down by biological processes when the rate of removal is approximately exponential.
Toxic chemicals with a long biological half-life (such as some pesticides) will tend to accumulate in the body and are, therefore, more likely to be harmful. A substance with a short biological half-life may still accumulate if a portion of it it becomes tightly bound to bone or other tissues, even if most of it is quickly cleared from the body.
(21 Mar 1998)
vegetative life The simple metabolic and reproductive activity of humans or animals, apart from the exercise of conscious mental or psychic processes.
(05 Mar 2000)
germ-free life Animals not contaminated by or associated with any foreign organisms.
(12 Dec 1998)
change of life Colloquialism for menopause, climacteric.
(05 Mar 2000)
RNA life <biology, molecular biology> A hypothetical life form lacking DNA and protein which may have existed on early earth and in which RNA served both a genetic coding and a catalytic function.
(23 Aug 1998)
physical half-life The time required for half the atoms of a radionuclide to undergo disintegration.
(05 Mar 2000)
wrongful life In civil law a cause of action which alleges that a defendant has wrongfully caused a child to be born.
(12 Dec 1998)
postnatal life That interval of life after birth; in man, usually divided into periods: neonatal, infancy, childhood, adolescence, and adulthood.
(05 Mar 2000)
half-life 1. <pharmacology> The period over which the concentration of a specified chemical or drug takes to fall to half its original concentration in the specified fluid or blood.
2. <radiobiology> The time required to reduce the amount of a radionuclide to one-half the amount originally present. Physical or radioactive half-life refers to reduction of activity by radioactive decay, biological half-life refers to biological elimination from the body and effective half-life refers to the combined action of radioactive decay and biological elimination.
(16 Dec 1997)
prenatal life That interval of life between conception and birth; in humans, usually divided into embryonic and foetal periods.
(05 Mar 2000)
sexual life In psychiatry and psychoanalysis, the specifically erotic or sexual interests, fantasies, inclinations, and conduct of the patient.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • life preserver
    (¼öÁß) ±¸¸í´ë
  • life science
    »ý¸í°úÇÐ(»ý¹°ÇÐ,»ýÈ­ÇÐ,ÀÇÇÐ,½É¸®ÇÐ µûÀ§)
  • life sentence
    Á¾½ÅÇü;¹«±â¡¿ª
  • life span
    (»ý¸íüÀÇ) ¼ö¸í
  • middle life
    Áß³â;Áß·ùÀÇ »ýȰ
  • natural life
    õ¼ö;õ¸í;¼ö¸í
  • night life
    ¹ãÀÇ À¯Èï;¹ã³îÀÌ
  • product life cycle
    Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ
  • real life
    ½Ç»ýȰ(¼Ò¼³.¿¬±Ø¿¡ ´ëÇØ¼­)
  • real-life
    ½Ç»ýȰ(Çö½Ç)ÀÇ
  • right-to-life
    ÀӽŠÁßÀý¿¡ ¹Ý´ëÇÏ´Â;-lifer ÀӽŠÁßÀý ±ÝÁö¹ý ÁöÁöÀÚ
  • shelf life
    (Æ÷Àå ½Äǰ µûÀ§ÀÇ)º¸Á¸ ±â°£
  • still life
    Á¤¹°(È­)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á